On behalf of the Journal of Molecular Cancer, as Editor-in-Chief, it is my distinct honour and privilege to welcome you.

The Journal of Molecular Cancer aims to disseminate knowledge and advance discussion through the publication of peer-reviewed, high quality research papers on all topics related to Molecular Cancer. Huge accentuation is laid on the current trends in Molecular cancer research along with key significant themes of chemistry. . The open access journal is published by Pulsus Publishing who hosts around 215 open access peer-reviewed journals as well as organizes more than 100 International scientific Conferences.

Background: Genotyping is crucial to the identification of genetic markers underlying development of neoplastic T cell diseases and individual molecular monitoring of minimal residual disease. However, these methods need to fulfill the principles of analytical validation to determine their suitability to assess single point mutation in target genes.
Methods: This review outlines current knowledge of the genetics of various forms of ALCL and new genetic markers in ALK-negative ALCL frequently recurred in Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). For the appropriate choice of any method, several criteria must be considered: i) known genetic variants in a given cancer gene; ii) diffusion and availability of large platforms and required equipment; iii) suitability of tests for routine diagnostics; iv) capacity of methods to offer a specific and sensitive detection of mutant alleles within great excess of wild-type alleles in a given sample; v) cost-effectiveness.
Conclusions: This review is intended to provide the reader with a better understanding of the various technologies available in the routine clinical laboratory for early detection of genetic markers of cancer T cell. Considerations about ways to most properly assess the analytical performance of these methods, are also given. Based on the criteria proposed here, lab managers, surgeons and clinicians may evaluate advantages and limitations of the different analytical platforms and possibly identify the most appropriate one according to specific operative settings for management of BIA-ALCL patients

Manuscripts can be uploaded at Online Manuscript Submission System

Regards,
Julia Gillard
Managing Editor
Journal of Molecular Cancer
molcancer@medicalres.org
Whats App: +1-947-33-4405